Concepts (233)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 21 | 2013 | 849 | 2.300 |
Why?
|
| Hypolipidemic Agents | 14 | 2009 | 190 | 1.850 |
Why?
|
| Dyslipidemias | 7 | 2010 | 235 | 1.690 |
Why?
|
| Anticholesteremic Agents | 14 | 2009 | 256 | 1.620 |
Why?
|
| Coronary Artery Disease | 12 | 2014 | 1011 | 1.300 |
Why?
|
| Heptanoic Acids | 6 | 2013 | 96 | 1.260 |
Why?
|
| Lipoproteins, HDL | 4 | 2012 | 144 | 1.220 |
Why?
|
| Atherosclerosis | 6 | 2012 | 935 | 1.180 |
Why?
|
| Simvastatin | 6 | 2009 | 106 | 1.110 |
Why?
|
| Coronary Disease | 10 | 2007 | 764 | 1.080 |
Why?
|
| Azetidines | 4 | 2009 | 87 | 1.010 |
Why?
|
| Hyperlipidemias | 7 | 2005 | 235 | 0.990 |
Why?
|
| Pyrroles | 5 | 2013 | 576 | 0.960 |
Why?
|
| Cholesterol, HDL | 8 | 2012 | 341 | 0.930 |
Why?
|
| Cholesterol, LDL | 14 | 2006 | 565 | 0.820 |
Why?
|
| Pravastatin | 4 | 2008 | 34 | 0.610 |
Why?
|
| Clinical Trials as Topic | 12 | 2008 | 3719 | 0.580 |
Why?
|
| Hypercholesterolemia | 6 | 2005 | 259 | 0.530 |
Why?
|
| Coronary Artery Bypass | 5 | 2014 | 708 | 0.480 |
Why?
|
| Angioplasty, Balloon, Coronary | 4 | 2014 | 314 | 0.480 |
Why?
|
| Hypolipoproteinemias | 1 | 2013 | 2 | 0.460 |
Why?
|
| Musculoskeletal Pain | 1 | 2013 | 21 | 0.460 |
Why?
|
| Drug-Eluting Stents | 1 | 2014 | 131 | 0.450 |
Why?
|
| Diabetes Complications | 1 | 2014 | 305 | 0.420 |
Why?
|
| Rhabdomyolysis | 2 | 2003 | 52 | 0.420 |
Why?
|
| Cardiovascular Diseases | 4 | 2007 | 2195 | 0.410 |
Why?
|
| Muscle, Skeletal | 2 | 2013 | 1270 | 0.400 |
Why?
|
| Niacin | 3 | 2009 | 61 | 0.400 |
Why?
|
| Oxidative Stress | 4 | 2012 | 1129 | 0.400 |
Why?
|
| Arteriosclerosis | 3 | 2002 | 185 | 0.390 |
Why?
|
| Hyperlipoproteinemia Type II | 3 | 2009 | 78 | 0.390 |
Why?
|
| Myocardial Infarction | 6 | 2008 | 1374 | 0.390 |
Why?
|
| Renin-Angiotensin System | 2 | 2001 | 103 | 0.360 |
Why?
|
| Hypertension | 3 | 2010 | 1503 | 0.340 |
Why?
|
| Heart Failure | 5 | 2009 | 2516 | 0.330 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2000 | 257 | 0.320 |
Why?
|
| Lipids | 3 | 2009 | 644 | 0.310 |
Why?
|
| Lipoproteins, LDL | 2 | 2006 | 163 | 0.310 |
Why?
|
| Ezetimibe | 4 | 2009 | 101 | 0.290 |
Why?
|
| Diabetes Mellitus | 2 | 2008 | 1054 | 0.290 |
Why?
|
| Angina, Unstable | 2 | 2005 | 70 | 0.270 |
Why?
|
| Inflammation Mediators | 1 | 2007 | 423 | 0.260 |
Why?
|
| Tumor Necrosis Factor-alpha | 5 | 2007 | 1538 | 0.250 |
Why?
|
| Sympathetic Nervous System | 1 | 2005 | 159 | 0.250 |
Why?
|
| Humans | 61 | 2014 | 261506 | 0.250 |
Why?
|
| Allylamine | 1 | 2004 | 11 | 0.250 |
Why?
|
| Randomized Controlled Trials as Topic | 7 | 2008 | 2594 | 0.250 |
Why?
|
| Cardiomyopathies | 2 | 2009 | 610 | 0.230 |
Why?
|
| Cholesterol | 4 | 2004 | 658 | 0.230 |
Why?
|
| Tyrosine | 2 | 2002 | 498 | 0.230 |
Why?
|
| Aortic Valve Stenosis | 1 | 2009 | 476 | 0.230 |
Why?
|
| Risk Factors | 12 | 2010 | 17523 | 0.230 |
Why?
|
| Intestinal Absorption | 1 | 2004 | 211 | 0.230 |
Why?
|
| Homeostasis | 1 | 2008 | 950 | 0.220 |
Why?
|
| Drug Therapy, Combination | 6 | 2009 | 2315 | 0.220 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2002 | 100 | 0.210 |
Why?
|
| Myocardial Ischemia | 4 | 2000 | 435 | 0.210 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2003 | 160 | 0.210 |
Why?
|
| Energy Metabolism | 1 | 2008 | 992 | 0.210 |
Why?
|
| Insulin | 1 | 2008 | 1454 | 0.210 |
Why?
|
| Inflammation | 3 | 2007 | 2522 | 0.200 |
Why?
|
| Metabolic Syndrome | 1 | 2004 | 353 | 0.190 |
Why?
|
| Endothelium, Vascular | 4 | 2010 | 891 | 0.190 |
Why?
|
| Myositis | 1 | 2001 | 79 | 0.190 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2008 | 1362 | 0.180 |
Why?
|
| Cardiovascular Physiological Phenomena | 1 | 2000 | 44 | 0.180 |
Why?
|
| Biological Transport | 2 | 2012 | 597 | 0.180 |
Why?
|
| Liver | 3 | 2008 | 2961 | 0.170 |
Why?
|
| Lipoproteins, VLDL | 2 | 2009 | 89 | 0.160 |
Why?
|
| Pyridines | 2 | 2003 | 1244 | 0.160 |
Why?
|
| Obesity | 2 | 2008 | 2884 | 0.160 |
Why?
|
| Central Nervous System | 1 | 2000 | 436 | 0.160 |
Why?
|
| Triglycerides | 5 | 2007 | 603 | 0.150 |
Why?
|
| Endocarditis | 1 | 1997 | 125 | 0.130 |
Why?
|
| Blood Coagulation | 2 | 2011 | 185 | 0.130 |
Why?
|
| Lipoproteins | 3 | 2009 | 252 | 0.130 |
Why?
|
| Coronary Circulation | 2 | 2008 | 253 | 0.110 |
Why?
|
| Fatty Acids, Monounsaturated | 3 | 1999 | 71 | 0.110 |
Why?
|
| Diuretics | 1 | 2013 | 170 | 0.110 |
Why?
|
| Lovastatin | 1 | 1992 | 58 | 0.110 |
Why?
|
| Multicenter Studies as Topic | 2 | 2005 | 543 | 0.110 |
Why?
|
| Insulin Resistance | 2 | 2008 | 731 | 0.100 |
Why?
|
| Prognosis | 4 | 2012 | 21713 | 0.100 |
Why?
|
| Disease Progression | 5 | 2010 | 6682 | 0.100 |
Why?
|
| Drug Interactions | 3 | 2000 | 553 | 0.100 |
Why?
|
| Male | 22 | 2014 | 123000 | 0.100 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2005 | 323 | 0.090 |
Why?
|
| Vasoconstriction | 1 | 2010 | 104 | 0.090 |
Why?
|
| Oxidation-Reduction | 1 | 2012 | 717 | 0.090 |
Why?
|
| Double-Blind Method | 5 | 2009 | 2588 | 0.090 |
Why?
|
| Signal Transduction | 1 | 2008 | 11965 | 0.090 |
Why?
|
| Lipoproteins, IDL | 1 | 2009 | 5 | 0.090 |
Why?
|
| Female | 19 | 2014 | 141928 | 0.090 |
Why?
|
| Antioxidants | 1 | 2012 | 507 | 0.080 |
Why?
|
| Sensitivity and Specificity | 2 | 2011 | 4971 | 0.080 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2008 | 65 | 0.080 |
Why?
|
| Coronary Occlusion | 1 | 2008 | 31 | 0.080 |
Why?
|
| Cholestyramine Resin | 3 | 1996 | 17 | 0.080 |
Why?
|
| Resistin | 1 | 2007 | 39 | 0.080 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2013 | 563 | 0.080 |
Why?
|
| Acute-Phase Proteins | 1 | 2007 | 79 | 0.080 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2001 | 5539 | 0.080 |
Why?
|
| Indoles | 3 | 1999 | 1009 | 0.070 |
Why?
|
| Gemfibrozil | 2 | 1996 | 6 | 0.070 |
Why?
|
| Prospective Studies | 3 | 2013 | 12873 | 0.070 |
Why?
|
| Neoplasms | 1 | 2013 | 15193 | 0.070 |
Why?
|
| Treatment Outcome | 7 | 2006 | 32848 | 0.070 |
Why?
|
| Adiponectin | 1 | 2007 | 163 | 0.070 |
Why?
|
| Myocardium | 2 | 2005 | 1313 | 0.070 |
Why?
|
| Colestipol | 2 | 1996 | 7 | 0.070 |
Why?
|
| Parasympathetic Nervous System | 1 | 2005 | 26 | 0.070 |
Why?
|
| Leptin | 1 | 2007 | 295 | 0.070 |
Why?
|
| Survival Rate | 3 | 2006 | 12221 | 0.070 |
Why?
|
| Apolipoprotein A-I | 1 | 2005 | 84 | 0.060 |
Why?
|
| Biomarkers | 3 | 2005 | 5047 | 0.060 |
Why?
|
| Acute Coronary Syndrome | 1 | 2008 | 259 | 0.060 |
Why?
|
| Heart Transplantation | 2 | 2005 | 908 | 0.060 |
Why?
|
| Risk Assessment | 2 | 2012 | 6869 | 0.060 |
Why?
|
| Colesevelam Hydrochloride | 1 | 2004 | 4 | 0.060 |
Why?
|
| Blood Pressure | 1 | 2010 | 1467 | 0.060 |
Why?
|
| Greece | 1 | 2003 | 22 | 0.060 |
Why?
|
| Lipid Metabolism | 1 | 2006 | 483 | 0.060 |
Why?
|
| Platelet Function Tests | 1 | 2002 | 50 | 0.050 |
Why?
|
| United Kingdom | 1 | 2003 | 257 | 0.050 |
Why?
|
| Risk Reduction Behavior | 1 | 2003 | 227 | 0.050 |
Why?
|
| C-Reactive Protein | 1 | 2005 | 527 | 0.050 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2001 | 184 | 0.050 |
Why?
|
| Radiology, Interventional | 1 | 2002 | 138 | 0.050 |
Why?
|
| Cardiac Catheterization | 2 | 2002 | 687 | 0.050 |
Why?
|
| Coronary Thrombosis | 1 | 1999 | 44 | 0.040 |
Why?
|
| Animals | 5 | 2008 | 59536 | 0.040 |
Why?
|
| Isosorbide Dinitrate | 1 | 1998 | 4 | 0.040 |
Why?
|
| Diltiazem | 1 | 1998 | 12 | 0.040 |
Why?
|
| Xylenes | 1 | 1998 | 12 | 0.040 |
Why?
|
| Vasoconstrictor Agents | 1 | 1999 | 151 | 0.040 |
Why?
|
| Metoprolol | 1 | 1998 | 28 | 0.040 |
Why?
|
| Bone Nails | 1 | 1998 | 24 | 0.040 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2002 | 444 | 0.040 |
Why?
|
| Premedication | 1 | 1998 | 135 | 0.040 |
Why?
|
| Fracture Fixation, Intramedullary | 1 | 1998 | 32 | 0.040 |
Why?
|
| Tibial Fractures | 1 | 1998 | 58 | 0.040 |
Why?
|
| Chlorhexidine | 1 | 1998 | 88 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2005 | 4938 | 0.040 |
Why?
|
| Neovascularization, Physiologic | 1 | 2000 | 345 | 0.040 |
Why?
|
| Cocaine | 1 | 1999 | 233 | 0.040 |
Why?
|
| Adjuvants, Immunologic | 1 | 2001 | 657 | 0.040 |
Why?
|
| Fistula | 1 | 1998 | 76 | 0.040 |
Why?
|
| Immunoglobulin G | 1 | 2001 | 1021 | 0.040 |
Why?
|
| Anti-Infective Agents, Local | 1 | 1998 | 121 | 0.040 |
Why?
|
| Collagen | 1 | 2000 | 752 | 0.040 |
Why?
|
| Vasodilator Agents | 1 | 1998 | 219 | 0.040 |
Why?
|
| Clofibrate | 1 | 1996 | 1 | 0.040 |
Why?
|
| Substance Abuse, Intravenous | 1 | 1997 | 42 | 0.040 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 1997 | 80 | 0.040 |
Why?
|
| Fibrinolytic Agents | 1 | 1999 | 324 | 0.040 |
Why?
|
| Enzyme Inhibitors | 2 | 1997 | 1879 | 0.040 |
Why?
|
| Prevalence | 1 | 2004 | 3260 | 0.040 |
Why?
|
| Vascular Patency | 1 | 1997 | 218 | 0.040 |
Why?
|
| Fenofibrate | 1 | 1996 | 57 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2006 | 2403 | 0.030 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2001 | 1555 | 0.030 |
Why?
|
| Visual Acuity | 1 | 2000 | 873 | 0.030 |
Why?
|
| Carotid Artery Diseases | 1 | 1997 | 196 | 0.030 |
Why?
|
| Middle Aged | 14 | 2013 | 86204 | 0.030 |
Why?
|
| Morbidity | 1 | 1997 | 397 | 0.030 |
Why?
|
| Lipoprotein(a) | 1 | 1996 | 113 | 0.030 |
Why?
|
| Probucol | 1 | 1994 | 2 | 0.030 |
Why?
|
| Clofibric Acid | 1 | 1994 | 4 | 0.030 |
Why?
|
| Fibric Acids | 1 | 1994 | 7 | 0.030 |
Why?
|
| Brain | 1 | 2008 | 4113 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 1998 | 945 | 0.030 |
Why?
|
| Stroke | 1 | 2003 | 1144 | 0.030 |
Why?
|
| Pulmonary Artery | 1 | 1998 | 499 | 0.030 |
Why?
|
| Staphylococcal Infections | 1 | 1998 | 672 | 0.030 |
Why?
|
| Coronary Vessels | 1 | 1997 | 665 | 0.030 |
Why?
|
| Adult | 11 | 2000 | 77950 | 0.030 |
Why?
|
| Polymorphism, Genetic | 1 | 1997 | 1450 | 0.030 |
Why?
|
| Coronary Angiography | 3 | 1999 | 598 | 0.020 |
Why?
|
| Echocardiography | 1 | 1997 | 1182 | 0.020 |
Why?
|
| Acyl Coenzyme A | 1 | 1991 | 33 | 0.020 |
Why?
|
| Aged | 8 | 2013 | 70117 | 0.020 |
Why?
|
| Heart-Assist Devices | 1 | 2000 | 1171 | 0.020 |
Why?
|
| Naphthalenes | 1 | 1991 | 83 | 0.020 |
Why?
|
| Age Factors | 1 | 1997 | 5377 | 0.020 |
Why?
|
| Cardiac Surgical Procedures | 1 | 1997 | 1237 | 0.020 |
Why?
|
| United States | 1 | 2004 | 15433 | 0.020 |
Why?
|
| Time Factors | 5 | 2005 | 12926 | 0.020 |
Why?
|
| Cardiovascular Agents | 2 | 1998 | 128 | 0.020 |
Why?
|
| Adolescent | 2 | 2005 | 31252 | 0.020 |
Why?
|
| Logistic Models | 1 | 2013 | 3441 | 0.020 |
Why?
|
| Adenosine | 2 | 1998 | 289 | 0.020 |
Why?
|
| Mutation | 1 | 2005 | 15179 | 0.020 |
Why?
|
| Hypertrophy | 1 | 2005 | 162 | 0.020 |
Why?
|
| HIV Infections | 1 | 1997 | 2134 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 1997 | 2992 | 0.020 |
Why?
|
| Hematologic Agents | 1 | 2001 | 13 | 0.010 |
Why?
|
| Etanercept | 1 | 2001 | 54 | 0.010 |
Why?
|
| Pentoxifylline | 1 | 2001 | 35 | 0.010 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2001 | 180 | 0.010 |
Why?
|
| Mice | 1 | 2001 | 34495 | 0.010 |
Why?
|
| Myocarditis | 1 | 2001 | 190 | 0.010 |
Why?
|
| Child | 1 | 2000 | 29154 | 0.010 |
Why?
|
| Myocytes, Cardiac | 1 | 2005 | 764 | 0.010 |
Why?
|
| Apolipoproteins | 1 | 1999 | 75 | 0.010 |
Why?
|
| Cardiac Output, Low | 1 | 1999 | 81 | 0.010 |
Why?
|
| Combined Modality Therapy | 2 | 2005 | 8865 | 0.010 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2000 | 244 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1998 | 418 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2013 | 5542 | 0.010 |
Why?
|
| Radionuclide Angiography | 1 | 1997 | 5 | 0.010 |
Why?
|
| Thallium Radioisotopes | 1 | 1997 | 20 | 0.010 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 1998 | 305 | 0.010 |
Why?
|
| Myocardial Contraction | 1 | 1999 | 291 | 0.010 |
Why?
|
| Rabbits | 1 | 1998 | 957 | 0.010 |
Why?
|
| Random Allocation | 1 | 1998 | 703 | 0.010 |
Why?
|
| Postprandial Period | 1 | 1996 | 85 | 0.010 |
Why?
|
| Lipolysis | 1 | 1996 | 108 | 0.010 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 1999 | 435 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 2013 | 37905 | 0.010 |
Why?
|
| Fasting | 1 | 1996 | 349 | 0.010 |
Why?
|
| Radiography | 1 | 1998 | 1904 | 0.010 |
Why?
|
| Regression Analysis | 1 | 1996 | 1546 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 1992 | 29902 | 0.010 |
Why?
|
| Cytokines | 1 | 2001 | 2809 | 0.010 |
Why?
|
| Gene Deletion | 1 | 1997 | 1442 | 0.010 |
Why?
|
| Pilot Projects | 1 | 1998 | 2803 | 0.010 |
Why?
|
| Placebos | 1 | 1991 | 437 | 0.010 |
Why?
|
| Genotype | 1 | 1997 | 4109 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2001 | 3869 | 0.010 |
Why?
|
| Survival Analysis | 1 | 1999 | 9180 | 0.000 |
Why?
|
| Disease Models, Animal | 1 | 1998 | 7222 | 0.000 |
Why?
|
| Follow-Up Studies | 1 | 1999 | 14889 | 0.000 |
Why?
|
| Severity of Illness Index | 1 | 1994 | 4320 | 0.000 |
Why?
|